Physician profile
John A Kern
NPI 1164591772
$2,027.97
in general payments reported to CMS, 2019-2025
14 companies · $247 in 2025
The $247 reported for 2025 was less than what a typical Vascular Surgery provider received nationally (typical 2025 total: $927).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2020: $212 · 2021: $367 · 2022: $465 · 2024: $614 · 2025: $247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $861.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $860.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $502.78 | 2024-2025 | Atricure Cryoice Cryoablation System (Cryo2), Synergy Ablation System, Atriclip Laa Exclusion System |
| Abbott Laboratories | $271.71 | 2020-2024 | Epic |
| Edwards Lifesciences Corporation | $256.94 | 2021 | |
| Angiodynamics, INC. | $205.28 | 2022 | |
| Bolton Medical INC | $154.05 | 2022 | |
| Medtronic Vascular, INC. | $153.22 | 2020 | |
| Abiomed | $130.42 | 2024 | Impella |
| W. L. Gore & Associates, INC. | $123.16 | 2019 | |
| Medtronic, INC. | $105.40 | 2022 | |
| Zimmer Biomet Holdings, INC. | $82.68 | 2024 | Sternalock |
| Werfen USA LLC | $23.47 | 2021 | |
| Medistim USA, INC. | $18.86 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Kern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.